The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.

Overall the authors found data from three clinical studies and four case reports and progression of SSc-ILD with a total of  57 SSc-ILD patients, who were treated with standard doses of tofacitinib (5 mg bid) or baricitinib (4 mg qd). The primary indication for JAKi use was active skin or musculoskeletal disease.

The American College of Rheumatology (ACR) released a summary of its new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis. This is the first ACR guideline about an integrative approach to Rheumatoid Arthritis (RA) and it is considered complementary to the ACR’s 2021 Guideline for the Treatment of RA, which covers pharmacologic therapies.